The Alzheimer’s Paradox: Early Diagnosis Is Here. Effective Treatment Isn’t

A blood test can see what the patient cannot

One of the most significant developments in Alzheimer’s research is happening in diagnostic laboratories. The plasma p-tau217 test measures phosphorylated tau, a protein associated with the pathological processes of Alzheimer’s. Studies have reported diagnostic performance approaching 96% in identifying amyloid pathology, with results comparable to established imaging and cerebrospinal fluid methods.

In May 2026, Roche received CE marking for its Elecsys pTau217 blood test, designed to identify or rule out amyloid pathology using a routine blood sample. In August, the test also received FDA clearance in the United States for patients aged 55 and older presenting with signs or symptoms of cognitive decline. This brings a sophisticated neurological biomarker much closer to ordinary clinical practice.

The implications are enormous. Alzheimer’s pathology can begin accumulating 15–20 years before recognizable symptoms appear. Researchers are developing increasingly sensitive tools to identify this process long before someone starts struggling with familiar names, conversations, or everyday tasks. Blood tests are also part of a broader diagnostic revolution. Researchers are investigating AI-assisted retinal imaging to identify neurological changes through routine eye examinations, alongside digital smell tests that measure early olfactory dysfunction. The objective is to make detection faster, cheaper, and accessible outside specialist memory clinics.

Click "Allow" to continue